SEC Company Response from NOVARTIS AG (NVS, NVSEF) (CIK 0001114448) (NVS) — May 17, 2013
NOVARTIS AG (NVS, NVSEF) (CIK 0001114448)
Date: May 17, 2013 · CIK: 0001114448 · Accession: 0001104659-13-042724
AI Filing Summary & Sentiment
File numbers found in text: 001-15024
Letter
Novartis AG Form 20-F for Fiscal Year Ended December 31, 2011 Filed January 25, 2012 File No. 001-15024
Re:
Dear Mr. Rosenberg:
We are in receipt of your letter addressed to Jonathan Symonds, our former Chief Financial Officer, dated May 3, 2013. As agreed in a May 15, 2013 telephone call between Barry Rosenfeld, of our affiliate Novartis Corporation, and Frank Wyman, Staff Accountant at SEC, we will respond to your letter on or before May 31, 2013.
Respectfully submitted,
Novartis AG
Show Raw Text
CORRESP 1 filename1.htm Novartis AG Postfach 4002 Basel Switzerland May 17, 2013 Mr. Jim B. Rosenberg Senior Assistant Chief Accountant US Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Novartis AG Form 20-F for Fiscal Year Ended December 31, 2011 Filed January 25, 2012 File No. 001-15024 Dear Mr. Rosenberg: We are in receipt of your letter addressed to Jonathan Symonds, our former Chief Financial Officer, dated May 3, 2013. As agreed in a May 15, 2013 telephone call between Barry Rosenfeld, of our affiliate Novartis Corporation, and Frank Wyman, Staff Accountant at SEC, we will respond to your letter on or before May 31, 2013. Respectfully submitted, Novartis AG /s/ HARRY KIRSCH /s/ FELIX R. EHRAT Harry Kirsch Felix R. Ehrat Chief Financial Officer General Counsel Novartis Group Novartis Group